Literature DB >> 2143209

IL-2 and IL-6 synergize to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells.

M J Smyth1, J R Ortaldo, W Bere, H Yagita, K Okumura, H A Young.   

Abstract

Our previous studies have demonstrated that high dose IL-2 (1000 U/ml) alone can induce human peripheral blood T cell pore-forming protein (PFP) mRNA expression and cytotoxic potential. We now report that the levels of IL-2 needed to induce these effects in T cells can be significantly reduced in the presence of IL-6. IL-6 and suboptimal doses of IL-2 (10 U/ml) were found to costimulate PFP mRNA expression and cytotoxic potential in resting human peripheral blood T cells, whereas IL-6 or low dose IL-2 alone had no effect. The induction of T cell PFP mRNA by IL-2/IL-6 was extremely rapid and increases in both PFP mRNA expression and cytotoxic potential were IL-6 dose dependent. The costimulatory effect of IL-6 did not appear to involve the IL-2/IL-2R pathway in as much as IL-6 did not induce IL-2 production or detectably increase IL-2R surface expression in T cells. These findings, in addition to the rapid induction of PFP mRNA by IL-2/IL-6, suggested that IL-6 can directly and independently provide an additional signal to augment the differentiation of CTL. In contrast to the results observed in T cells, IL-6 and IL-2 could enhance CD3- large granular lymphocyte (LGL) NK activity, but IL-6 either alone or in combination with IL-2 had no effect on constitutive PFP mRNA expression in resting LGL. These data further confirm that different mechanisms may be responsible for lymphokine activation of CTL and LGL in human peripheral blood. In particular it appears that IL-6 acts as a costimulatory signal with IL-2 in generating CTL and that IL-6 functions in part by acting in synergy with IL-2 to induce PFP, a major lytic protein involved in lymphocyte cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143209

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  The transcriptional control of the perforin locus.

Authors:  Matthew E Pipkin; Anjana Rao; Mathias G Lichtenheld
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Prevention of superantigen-induced down-regulation of T-cell mediated cytotoxic activity by IL-2 in vivo.

Authors:  H Belfrage; M Dohlsten; G Hedlund; T Kalland
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

3.  Subpopulations of mononuclear leukocytes associated with inhibition of Ehrlich ascites tumor growth by treatment with Bothrops jararaca venom.

Authors:  Mariana Morena de Vieira Santos; Reinaldo José da Silva; Márcia Guimarães da Silva; Denise Fecchio
Journal:  Mediators Inflamm       Date:  2004-02       Impact factor: 4.711

4.  In situ detection of activated cytotoxic cells in follicular lymphomas.

Authors:  M B Leger-Ravet; O Devergne; M Peuchmaur; P Solal-Celigny; N Brousse; P Gaulard; P Galanaud; D Emilie
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

5.  Interleukin-6 and interleukin-6 soluble receptor regulate proliferation of normal, human papillomavirus-immortalized, and carcinoma-derived cervical cells in vitro.

Authors:  M Iglesias; G D Plowman; C D Woodworth
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

6.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

7.  Perforin mRNA expression in the inflamed tissues of NZB/W F1 lupus mice decreases with methylprednisolone treatment.

Authors:  T Nakamura; I Ebihara; Y Tomino; K Okumura; H Koide
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

Review 8.  Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense.

Authors:  L Graeve; M Baumann; P C Heinrich
Journal:  Clin Investig       Date:  1993-08

9.  Augmentation by transferrin of IL-2-inducible killer activity and perforin production of human CD8+ T cells.

Authors:  A Nakamura; S Sone; R Nabioullin; K Sugihara; M Munekata; Y Nishioka; A Nii; T Ogura
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

10.  Characterization of a novel monoclonal antibody against human perforin using transfected cell lines.

Authors:  B C Schlesinger; L Cheng
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.